체액 채취 및 진단 시장 규모, 점유율, 동향 분석 보고서 : 샘플별, 제품별, 기술별, 용도별, 지역별, 부문별 예측(2025-2033년)

Body Fluid Collection And Diagnostics Market Summary

The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is anticipated to reach USD 61.99 billion by 2033, growing at a CAGR of 6.87% from 2025 to 2033. Rapid results, cost-effectiveness, and early prognosis of diseases are some of the factors contributing to the growth of the body fluid collection and diagnostics industry.

Advances in in-vitro diagnostic techniques are also playing a big role, as they make testing more accurate and efficient, encouraging wider use. For instance, in May 2022, TECHKON GmbH introduced a new method for analyzing body fluids that can assess medical parameters and diagnose diseases at the same time, making testing faster and more comprehensive.

The growing number of blood-related disorders is a key factor driving the demand for blood collection devices. Diseases such as anemia, sickle cell disease, hemophilia, and clotting disorders are becoming more common, along with blood cancers such as myeloma, lymphoma, and leukemia. In the U.S., blood cancer is particularly devastating, taking a life every nine minutes, which adds up to about 157 deaths each day or more than six every hour. In 2023, it's estimated that nearly 57,380 people in the U.S. will die from leukemia, lymphoma, or myeloma, accounting for almost 9.4% of all cancer-related deaths.

An estimated 437,337 individuals in the U.S. are either living with or in remission from leukemia, while around 879,242 people are in the same condition with lymphoma. Blood clots affect approximately 900,000 Americans each year, leading to about 100,000 deaths annually. Notably, fewer than one in four people show any noticeable signs or symptoms of a blood clot, underscoring the silent but significant impact of this condition.

The growing focus on early disease detection has significantly driven demand in the body fluid collection and diagnostics industry. Samples such as saliva, blood, urine, and semen are increasingly used to analyze biomarkers and other indicators for accurate and timely diagnosis. Moreover, numerous advancements and innovations have been made globally, further enhancing testing capabilities and expanding the range of conditions that can be detected through fluid-based diagnostics. For instance, in July 2021, Abbott announced of launching Panbio COVID-19 Antigen Self-Test in India to strengthen its rapid diagnostics product portfolio. It would support testing needs at work, at clinics, and at home. Further recently, In May 2024, the U.S. FDA approved the Rika Plasma Donation System featuring the iNomi Nomogram developed by Terumo Corporation. This product helps determine plasma collection volume based on an individual donor's weight, height, and hematocrit level at the time of donation.

Alzheimer's Disease (AD) is a severe neurodegenerative disease that requires the identification of precise biomarkers. The development and validation of early-stage biomarkers is a high research priority for existing diagnostics that can detect AD. Body-fluid biomarkers accurately reflect a synaptic failure in the brain and, as a result, could help improve diagnostic accuracy, track the course of the disease, and act as indicators for evaluating the effectiveness of early-onset disease-modifying therapies. In May 2022, the FDA authorized the marketing of a new test that could improve the diagnosis of AD. The Lumipulse test evaluates the ratio of -amyloid 1-40 and-amyloid 1-42 concentrations found in the human cerebral spinal fluid, which can help doctors in determining if a patient is expected to have amyloid plaques, a characteristic symptom of AD.

Body fluid samples contain a large number of naturally occurring biomarker proteins, which effectively show cancer progression. They are also utilized to find these biomarkers in order to validate the presence of cancer. For instance, in January 2022, scientists from the University of Illinois developed a tool that could detect cancer biomarkers in the body fluid samples. The quantification and detection of cancer-associated molecular biomarkers in such body fluids would help for minimally invasive cancer detection.

Furthermore, technological innovations in in-vitro diagnostics, such as high-throughput testing, automation, and integration of AI, have significantly enhanced diagnostic accuracy and efficiency. These advancements enable faster turnaround times and improved sensitivity, making body fluid diagnostic tools indispensable for modern healthcare. The availability of such innovative solutions supports the global adoption of these technologies.

Global Body Fluid Collection And Diagnostics Market Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global body fluid collection and diagnostics market report on the basis of sample, technology, application, product and region:

• Sample Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Saliva
• Urine
• Cerebrospinal Fluid
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Tests/Services
• Kits & Consumables
• Instruments
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence in situ hybridization (FISH)
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics & Monitoring
• Therapeutic Decision Making
• Prognostics & Screening
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Sample
  • 1.2.2. Product
  • 1.2.3. Technology
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Sample Outlook
  • 2.2.2. Product outlook
  • 2.2.3. Technology outlook
  • 2.2.4. Application outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Body Fluid Collection And Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing adoption of body fluid and collection kits for rapid diagnosis
    • 3.2.1.2. Increasing prevalence of non-communicable diseases
    • 3.2.1.3. Technological Advancements in Diagnostic Testing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of expertise to conduct at-home testing
    • 3.2.2.2. High cost of instruments
• 3.3. Body Fluid Collection And Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Body Fluid Collection And Diagnostics Market: Sample Estimates & Trend Analysis

• 4.1. Sample Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Body Fluid Collection And Diagnostics Market by Sample Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Blood
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD million)
• 4.6. Saliva
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Urine
  • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Cerebrospinal Fluid
  • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Body Fluid Collection And Diagnostics Market: Product Estimates & Trend Analysis

• 5.1. Product Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Body Fluid Collection And Diagnostics Market by Product Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Tests/Services
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD million)
• 5.6. Kits & Consumables
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Instruments
  • 5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Body Fluid Collection And Diagnostics Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Body Fluid Collection And Diagnostics Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Next-Generation Sequencing
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD million)
• 6.6. Polymerase Chain Reaction (PCR)
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Fluorescence in situ hybridization (FISH)
  • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Body Fluid Collection And Diagnostics Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2024 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Body Fluid Collection And Diagnostics Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Diagnostics & Monitoring
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD million)
• 7.6. Therapeutic Decision Making
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Prognostics & Screening
  • 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Body Fluid Collection And Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Thermo Fisher Scientific Inc.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Bio-Rad Laboratories
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Illumina, Inc
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Guardant Health
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. QIAGEN
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Johnson & Johnson
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Laboratory Corporation of America Holdings
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Biocept Inc
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. F. Hoffmann-La Roche Ltd.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. MDxHealth SA.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives